Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Gibco CTS AAV-MAX Helper-Free AAV Production System, a new all-in-one solution ...

Adeno-associated viruses (AAVs) have transformed the landscape of gene therapy product development. In the past, allocating precious samples for aggregate testing was completely impractical given the ...

Journal in the field and provides all-inclusive access to the critical pillars of human gene therapy: research, methods, and clinical applications. Recent clinical trials utilizing high doses of adeno ...

Plasmids are essential for the development of viral vectors used to manufacture novel gene therapies and viral vaccines. Aldevron is supporting the innovation of drug developers in this space by ...

FARGO, N.D.--(BUSINESS WIRE)--Aldevron announced today the immediate availability of rep/cap plasmids pALD-AAV2, AAV5 and AAV6 to support AAV viral vector manufacturing. All three rep/cap plasmids are ...

Dyno Therapeutics CEO and co-founder Eric Kelsic, PhD, likens his company’s development of transformative AI-designed adeno-associated virus (AAV) vectors for gene therapy to climbing a mountain—a ...

-Oral Presentation at ESGCT Highlights Potential of JCR’s Proprietary JUST-AAV Platform to Facilitate More Efficient Delivery While Reducing Liver Tropism- JCR Pharmaceuticals Co., Ltd. (TSE 4552; ...